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Background & Aims: Liver inﬂammatory diseases associated
with cancer promoting somatic oncogene mutations are increas-
ing in frequency. Preclinical cancer models that allow for the
study of early tumor progression are often protracted, which
limits the experimental study parameters due to time and expense.
Here we report a robust inexpensive approach using Sleeping
Beauty transposition (SBT) delivery of oncogenes along with
Gaussia Luciferase expression vector GLuc, to assess de novo liver
tumor progression, as well as the detection of innate immune
responses or responses induced by therapeutic intervention.
Methods: Tracking de novo liver tumor progression with GLuc
was demonstrated in models of hepatocellular carcinoma (HCC)
or adenoma (HCA) initiated by hydrodynamic delivery of SBT
oncogenes.
Results: Rising serum luciferase levels correlated directly with
increasing liver tumor burden and eventual morbidity. Early
detection of hepatocyte apoptosis from mice with MET+CAT
transfected hepatocytes was associated with a transient delay
in HCC growth mediated by a CD8+ T-cell response against trans-
formed hepatocytes. Furthermore, mice that lack B cells or
macrophages had an increase in TUNEL+ hepatocytes following
liver MET transfection demonstrating that these cells provide
protection from MET-induced hepatocyte apoptosis. Treatment
with IL-18+IL-12 of mice displaying established HCC decreased
tumor burden which was associated with decreased levels of
serum luciferase.Journal of Hepatology 20
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This revealed tumor-induced immunologic responses and was
beneﬁcial in monitoring the efﬁcacy of therapeutic interventions.
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Up to 70–90% of all liver cancers are detected in patients suffer-
ing from chronic inﬂammatory liver diseases due to obesity,
chronic hepatitis C and liver ﬂuke infections that increase the fre-
quency of deleterious somatic mutations in oncogenes and tumor
suppressor genes [1–9]. Because liver inﬂammatory diseases due
to obesity [10] and hepatitis C infections [11] have a globally
increasing frequency, it is important to understand which
somatic mutations in oncogenes drive liver cancer development
and/or progression and how inﬂammation facilitates this process.
The advent of Sleeping Beauty transposition (SBT) technology
has provided experimental tools to investigate how mutations
of oncogenes lead to the development of liver cancer [12,13]. This
non-viral-based gene transfection system can be used to induce
liver tumors by stably integrating oncogenes into hepatocytes.
The induction of tumors using the SBT system allows the analysis
of how inﬂammation and tumor immunity regulate the entire
spectrum of tumor growth including the early stages of neoplasia,
which cannot be addressed using transplantable tumors.
Although carcinogens such as diethylnitrosamine (DEN) also
allow us to study liver tumor formation, butl often induces a
myriad of undeﬁned mutations and off target events, while the
SBT system can be best used to study how speciﬁc oncogenes
collaborate in the formation of tumors.
Mouse cancer models using SBT, carcinogens and transgenic
mice are amenable for the study of tumor formation at the early
stages of neoplasia but are limited by the variable and often pro-
tracted time for development/progression of tumors, depending
on the oncogene combinations used for initiation. In vivo imaging
could be used to follow tumor progression but this approach can
be prohibitively expensive, limited by the number of mice that15 vol. 63 j 1181–1189
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can be scanned and requires dedicated staff to run complex
instrumentation. Thus, a tumor-tracking method that could be
used sequentially in individual mice over a long period of time
would allow an assessment of tumor status in real-time. Such
an approach may reveal therapeutic windows, be used to extrap-
olate tumor burden and survival times and potentially elucidate
immunoregulatory events.
In this study, we investigated the use of the SBT GLuc vector
for tracking nonlinear oncogene-induced liver tumor progression.
Using two distinct de novo liver tumor models, we demonstrated
that the level of serum luciferase released by GLuc vector
integrated in hepatocytes (GLuc+ hepatocytes) signiﬁcantly
correlated with the volume of liver tumors, thereby providing a
minimally-invasive method to track in living mice the growth
of de novo-generated liver tumors. Using this minimally-
invasive method, parameters can be measured that would other-
wise require euthanasia of mouse cohorts with an associated
higher experimental cost. The evaluation of immunogenic de
novo liver tumors using GLuc+ hepatocytes also allowed us to
identify inﬂection points that revealed CD8+ T-cell mediated
transient tumor inhibitory effects during tumor progression.
Concordantly, we show for the ﬁrst time that stable expression
of luciferase by hepatocytes can also be used to efﬁciently track,
in real-time, the outcome of therapies against oncogene-driven
de novo liver tumors.Materials and methods
Plasmid constructs
Plasmids encoding the Sleeping Beauty transposase (HSB2) and transposons con-
taining human c-Met (MET) and empty vector control (PT3), were a generous gift
from Dr. Xin Chen (UCSF, San Francisco, Ca.). Transposon constructs containing
D90Nb-catenin (CAT) and Myr-AKT (AKT) were previously reported [14]. The
gene for Gaussia Luciferase was PCR-ampliﬁed and cloned into pENTR
(Invitrogen) and subsequently Gateway-cloned into the PT3 destination vector
to produce a Gaussia luciferase transposon (GLuc) vector.Experimental model
C57/BL6J (wild-type [WT]), B6.129S2-Cd8a (CD8/), B6.129S2-Cd4/J (CD4/),
B6.129S2-lgh-6 (Bcell/) and CD1d/ (NKT/) mice were purchased from The
Jackson Laboratory and were bred and maintained at the Frederick National
Laboratory in a speciﬁc pathogen free facility in accordance with an approved
Animal Care and Use Protocol. Oncogene constructs were delivered to hepato-
cytes using the hydrodynamic transfection technique. Brieﬂy, constructs
containing either MET+CAT or AKT+CAT along with HSB and GLuc vector were
mixed in saline at a volume of 10% vol/mouse weight and injected via tail vein
into aged and sex matched 8–12 week old C57/BL6J or B6.129S2-Cd8a mice over
5–7 seconds as previously described [12]. MET+CAT induces liver tumors with a
pathology consistent with hepatocellular carcinoma (HCC) while AKT+CAT
induces liver tumors histopathologically characterized as hepatocellular adenoma
(HCA) [14].Immunohistochemistry (IHC) staining and analysis
Liver tissues were ﬁxed with 10% normal buffered formalin overnight and then
transferred to 70% ethanol. Parafﬁn blocks were made from the ﬁxed tissues.
Slides cut from the blocks were analyzed for apoptosis using TUNEL staining, pro-
liferation using BrdU at 1:50 (Invitrogen Life Technologies), b-catenin at 1:200
(Abcam) and N-ras (F155 Santa Cruz). For IHC slide analysis, ﬁve
non-overlapping pictures were taken from at least two separate lobes and images
were analyzed using CellProﬁler (http://www.cellproﬁler.org/) with modiﬁed
Ki67 pipeline.1182 Journal of Hepatology 2015Immunotherapeutic regimen
Recombinant murine IL-12 and IL-18 was purchased from PeproTech Inc. (Rocky
Hill, NJ). Stock aliquots of cytokines were diluted with HBSS and mice were
injected intraperitoneally with vehicle control (VC) or IL-12 (0.3 lg) + IL-18
(0.3 lg) on days 20–24 and 28–31 post-initiation of liver tumors with MET+CAT
oncogenes.
qPCR quantitation of oncogenes in the liver
Livers were harvested and snap frozen on a dry ice and 2-Methylbutane mixture
for later manipulations. Frozen livers were mechanically shattered into small
fragments and genomic DNA was isolated using a Gentra Puregene Tissue Kit
(Qiagen) according to manufactures instructions. Oncogene copy number per
100 ng of liver DNA was determined using qPCR analysis with TaqMan
probes MET (Hs 01564484_m1), CTNNB1 (CAT) (Hs 00355049_m1), and AKT
(mm 01331626_m1) (ABI) and comparing it to a standard curve made using
the oncogene plasmids.
Tumor assessment by magnetic resonance imaging (MRI)
Animal imaging was performed by Frederick National Laboratory Small Animal
Imaging Program. MRI was performed with a 3.0T clinical scanner (Philips Intera
Achieva, Philips Medical Systems, Einthoven, NL) to detect the onset of tumors,
monitor their progression, and track the changes in the liver volume biweekly.
Data was acquired using a 40-mm diameter solenoid receiver coil (Philips
Research, Hamburg, Germany). The mice were anesthetized in an induction
chamber with 3% isoﬂurane in O2 at 1 L/min ﬂow rate and then placed in a custom
made mouse holder within the imaging coil. During an imaging session, the
anesthesia level was modiﬁed between 1.5–2.0% isoﬂurane to maintain a
40 bpm pulmonary rate, and their physiology monitored (Biopac System Inc.,
Goleta, CA). Body temperature was maintained at 37 C by supplying warm air
(Small Animal Instruments, Inc., Stony Brook, NY) around the mouse holder. Multi
slice T2 weighted turbo spin echo (T2w-TSE) sequence was applied in coronal
view with respiratory triggering to minimize the motion artifacts. An imaging
volume of 36  27  18 mm was chosen to cover the mouse abdominal cavity.
The images were acquired with a repetition time (TR) 4500 ms, echo time (TE)
65 ms, with an in plane resolution of 0.190  0.190 mm, and slice thickness
0.5 mm. Serial images obtained in 8 biweekly consecutive imaging sessions were
used to calculate the changes in tumor and liver volumes.
Gaussia Luciferase assay
Mouse blood was collected using retro orbital bleeds in a serum separator tube
(Becton Dickinson co.) and then serum was recovered by centrifuging tubes for
3 minutes at 20,000 g and then 5 ll of serum was added to 100 ll of PBS and pla-
ted on a 96 well ﬂat bottom white polystyrene assay plate (Costar 3362). Serum
luciferase levels were determined using the BioLux Gaussia Luciferase Assay kit
(New England BioLabs) according to manufacturer’s direction and luminescence
measurements were acquired using FLUOstar Omega microplate reader (BMG
LABTECH) after controlled injection of 50 ll of substrate mixture into plates
containing the serum PBS mixture.
Liver leukocyte isolation and ﬂow cytometric analysis
Liver leukocytes were isolated as previously described [15]. Isolated leukocytes
were counted and 1  106 cells were Fc-blocked with monoclonal 2.4G2 prior
to staining with appropriately titered monoclonal antibodies (CD8a PerCP and
PD-1 PE; eBioscience) used in conjunction with Live/Dead reagent; Invitrogen).
Data was collected using a LSRII Special Order System equipped with solid state
blue (488 nm), red (640 nm) and violet (405 nm) lasers and then analyzed using
FloJo Vx0.6.
Transfection of mouse hepatoma Hepa1–6 cells
Hepa1–6 cells were maintained in DMEM containing 1.45 g of glucose/liter
(Sigma), supplemented with 2 mM glutamine, 50 lg/ml gentamycin sulfate,
and 10% (v/v) heat-inactivated fetal calf serum. Targefect-Hepatocyte reagent
(Targeting Systems, CA) was used for PT3-GFP or PT3-MET plasmid transfection
into Hepa1–6 cells according to the manufacturer’s protocol. Cells were harvestedvol. 63 j 1181–1189
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24 h or 72 h post-transfection for apoptosis detection. Cell apoptosis was detected
using PE Annexin V Apoptosis Detection Kit I according to manufacturer’s proto-
col (BD Bioscience).Statistical analysis
Data in this study were analyzed with linear mixed effects hierarchical models,
analysis of variance and covariance, Kaplan-Meier and Cox Proportional Hazards
regression methods, correlation and (weighted) regression analysis, post hoc tests
(e.g., Tukey’s test for multiple comparisons) and non-parametric methods (e.g.,
Wilcoxon’s test). Repeated measures analyses (in which ‘repeated’ measurements
are recorded for the same animal on more than one occasion) and mixed effects
models take into consideration the correlation/covariation of responses within
the same animal over time [16,17]. Homogeneity of variance and covariance
assumptions were routinely tested in model ﬁts. Probability values less than
0.05 were considered signiﬁcant.Results
Serum GLuc levels correlate with MET+CAT oncogene-induced liver
tumor burden
Ectopic expression of foreign proteins in mice can lead to an
immune response against the protein and the tissues expressing
the protein [18,19]. To determine whether secreted GLuc could be
stably expressed in the liver and not immunologically rejected,
we delivered GLuc expression vector hydrodynamically to the
liver via SBT, with or without transposase (HSB2) [12]. Trans-
posase HSB2 causes genomic insertion of the transposon ran-
domly at AT-dinucleotide sites. In the absence of HSB2, the
GLuc transposon does not integrate into the hepatocyte genome.
Serum expression kinetics of luciferase was analyzed in C57/Bl6
mice injected with GLuc (non-integrated) or GLuc+HSB2 vectors
(integrated) (Supplementary Fig. 1). Stable constitutive expres-
sion of luciferase was observed by day 3 in mice given
GLuc+HSB2. The levels of serum Gaussia Luciferase were signiﬁ-
cantly higher in mice given GLuc+HSB2 vectors compared to mice
given GLuc vector alone (post hoc Tukey’s test; p <0.0001). Con-
versely, there was no signiﬁcant difference in luciferase levels
after day 3 between the serum of mice given GLuc alone and con-
trol serum from naïve mice. These data show that hepatocytes
with integrated GLuc vector (GLuc+ hepatocytes) stably express
constitutive levels of luciferase while luciferase levels of
non-integrated GLuc are rapidly lost, returning to baseline level
by day 3.
Because hepatocytes with integrated GLuc stably express
luciferase under homeostatic conditions, we next tested whether
this technique could be used to track hepatocyte proliferation.
We hypothesized that the constitutively expressed levels of
luciferase should rise when GLuc+ hepatocytes are induced by
oncogenes to proliferate. De novo HCC formation was initiated
by hydrodynamic transfection of 4 lg of GLuc vector and escalat-
ing concentrations of MET+CAT oncogenes in combination with
HSB2 [14]. At days 30 and 56 mice that received MET+CAT doses
of 25, 12.5, and 5 lg showed signiﬁcantly higher serum luciferase
levels compared to mice injected with PT3 controls or lower con-
centration of MET+CAT (Supplementary Fig. 2A). To conﬁrm that
the signiﬁcant rise in luciferase levels with the higher MET+CAT
oncogene groups was due to tumor burden, mice were
euthanized at day 55 and tumor-bearing livers were weighed
(Supplementary Fig. 2B). A proportional relationship was
observed between the amount of MET+CAT oncogenes used toJournal of Hepatology 2015initiate tumors and their respective tumor-bearing liver weights
(Supplementary Fig. 2C). Linear regression analysis revealed a
signiﬁcant correlation between serum luciferase levels and the
weights of the tumor-bearing livers. To speciﬁcally determine if
serum luciferase levels correlated with liver tumor burden, we
quantitated the amount of integrated oncogenes in liver tissue
using qPCR and compared it with the levels of serum luciferase.
The copy number of MET and CAT oncogenes in 100 ng of geno-
mic DNA was then plotted against serum luciferase levels from
these same mice at day 55 (Supplementary Fig. 2D, E). Linear
regression analysis showed a signiﬁcant correlation between
the liver levels of either oncogene and serum luciferase levels.
Progression of AKT+CAT-initiated liver tumors originated in GLuc+
hepatocytes is accurately tracked by serum luciferase levels
To validate that hepatocytes with integrated GLuc vector could
also be used to track alternative models of de novo-initiated liver
tumors, we used AKT+CAT oncogenes that induce liver tumors
(HCA) that are histopathologically distinct from those induced
by MET+CAT (HCC) [14]. Furthermore, we wanted to determine
whether GLuc+ hepatocytes could be used to track liver tumor
progression throughout the oncogenic process. This is critical
because tumors can grow in complex three-dimensional nonlin-
ear tracks [20,21]. Mice were hydrodynamically transfected with
GLuc vector along with AKT+CAT oncogenes and HSB2. Tumor
progression was analyzed in real-time by measuring liver size
using MRI analysis on days 27, 41, 59, 66, 95, and 103. At day
27, normal liver morphology was evident. However, as
AKT+CAT-initiated tumors progress to day 103, tumor nodules
develop causing the liver to distend (Supplementary Fig. 3A).
Serum luciferase levels were quantitated on the same days of
MRI examination and a comparative analysis was done between
these two parameters (Supplementary Fig. 3B). Both MRI
liver analysis and serum luciferase levels revealed that
AKT+CAT-initiated liver tumors progress in a nonlinear manner.
Pearson correlations between serum luciferase levels and tumor
sizes for all three animals are extremely high: r4401 = 0.99
(p <0.0001), r4403 = 0.98 (p = 0.0005), and r4404 = 0.99
(p <0.0001). In addition, analysis of covariance showed that for
each animal, the proportionate relative luminescence units and
liver size measures were statistically parallel, demonstrating
the association between induced size changes in liver tumors
and levels of serum luciferase. Taken together, these data demon-
strate that a high degree of correlation exists between liver tumor
growth kinetics and levels of serum luciferase. Moreover, GLuc+
hepatocytes can be used to track the nonlinear progression of
de novo-initiated liver tumors.
Serum luciferase levels detect growth rate changes in oncogene-
induced liver tumors
The changes in kinetics of tumor progression relative to morbid-
ity can provide insights into the diversity of basic biological
mechanisms and/or immune recognition of tumors initiated by
different oncogenic events. We tested whether integration of
GLuc into hepatocytes provides a useful tool for detecting subtle
variations in tumor progression of pathologically distinct HCA
(AKT+CAT) or HCC (MET+CAT) [14]. By day 340, 90% and 70% of
mice transfected with AKT+CAT and MET+CAT, respectively, had
succumbed to the tumors (Fig. 1A), while all the mice given thevol. 63 j 1181–1189 1183
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Fig. 1. Morbidity analysis of mice with AKT+CAT and MET+CAT-initiated liver
tumors using GLuc integrated in the liver. GLuc (4 lg), AKT (20 lg) + CAT
(20 lg) and MET (20 lg) + CAT (20 lg) oncogenes along with HSB2 (4.4 lg) were
delivered to C57/Bl6 mice using hydrodynamic tail vein injection. (A) Kaplan-
Meier survival plot. (B) Serum luciferase levels days 0–218. (C) Serum luciferase
levels days 0–42. PT3 n = 5, AKT+CAT n = 10, MET+CAT n = 10, mean ± SEM. (D)
Liver sections were ApopTag Peroxidase stained using the TUNEL method on day
7 following initiation with MET or CAT oncogenes. (E and F) MET was
hydrodynamically injected into WT, CD1d/, CD8/, CD4/ or lgh-6 mice. For
NK cell and macrophage depletion (F) mice were treated with asGM1 or
Clodronate respectively on days 3 and 1 prior to MET delivery. On day 7 liver
tissue sections from (E and F) were stained for TUNEL counted on 5 non-
overlapping 100 ﬁelds from 3 individual mice per group using CellProﬁler. n = 3,
***p <0.0001 mean ± SEM. Mann-Whitney U test was used to determine
signiﬁcance.
Research ArticlePT3 control vector survived. In addition, the mortality rate of
AKT+CAT and MET+CAT transfected mice was similar (Fig. 1A),
serum luciferase levels measured at various time points indicated
intriguing differences in the kinetics and therefore in the biology
of AKT+CAT and MET+CAT-initiated tumor growth (Fig. 1B). Dur-
ing the early phase (days 10–42) of tumor growth, luciferase
levels in the sera from AKT+CAT-induced tumors increased, while
the levels in mice that received MET+CAT fell slightly below the
PT3 control (Fig. 1C). These data suggest the AKT+CAT oncogene
combination initially causes sustained proliferation of trans-
formed hepatocytes more effectively than the MET+CAT onco-
genes. However, starting at day 59, luciferase levels from both
groups rise approximately co-linearly (Fig. 1B). It remained to
be determined whether this difference in kinetics was due to
intrinsic characteristics in the induction and maintenance of pro-
liferation in the transformed hepatocytes, or rather to some other
biological factors such as differences in the ability of the immune
system to recognize and respond to these tumors. We speculated1184 Journal of Hepatology 2015that the human MET protein might be immunogenic in mice, and
when expressed on hepatocytes might elicit an immune response
resulting in detectable changes in tumor progression. To deter-
mine whether hepatocytes expressing the MET oncogene
undergo apoptosis we injected MET or CAT oncogenes into mice
and collected livers on day 7. Apoptotic hepatocytes were
detected by TUNEL staining of liver tissue sections (Fig. 1D).
TUNEL staining was more prevalent in the livers of mice that
received the MET oncogene compared to those that received CAT.
To determine if the increased MET-induced hepatocyte apop-
tosis was immune mediated, we ﬁrst examined the level of
non-speciﬁc TUNEL+ hepatocytes by immunohistochemistry in
naïve WT, NKT deﬁcient (CD1d/), CD8/, CD4/, and B cell/
(lgh-6) mice. We also examined the level of non-speciﬁc TUNEL+
hepatocytes in naïve mice depleted of NK cells and macrophages
using asGM1 and clodronate respectively. No change in the fre-
quency of TUNEL+ hepatocytes was observed in CD1d/, CD8/,
CD4/, B cell/ or in mice treated with clodronate or asGM1
compared to WT mice (Supplementary Fig. 4A). Next to deter-
mine if the increased MET-induced hepatocyte apoptosis was
immune mediated, we injected MET into CD1d/, CD8/,
CD4/ or B cell/ mice. We also injected MET into mice
depleted of NK cells and macrophages using asGM1 and clo-
dronate respectively. Livers were harvested on day 7 and TUNEL+
hepatocytes were quantitated using immunohistochemistry. A
signiﬁcant decrease in TUNEL+ hepatocytes was observed in the
CD8/ mice compared to WT mice (Fig. 1E), suggesting CD8 cells
are at least partially required for MET-induced hepatocyte
apoptosis. In contrast, the frequency of TUNEL+ hepatocytes
was increased in mice depleted of macrophages and Igh-6
deﬁcient mice (Fig. 1F), suggesting these cells may offer a partial
protection from MET-induced hepatocyte apoptosis.
Recently it was shown that oncogenic N-ras can induce
senescence in pre-malignant cells that are eliminated by CD4+ T
cells [22]. However, mice with MET transduced livers did not
express hepatocyte N-ras (Fig. 2A) or senescence marker
beta-galactosidase at days 10 and 30 (Fig. 2B), suggesting MET
does not induce the senescence pathway in hepatocytes.
The ability of MET oncogene to induce apoptosis directly was
also examined. Mouse hepatoma Hepa1–6 cells were transfected
with MET or GFP SBT vectors with greater than 20% transfection
efﬁciency determined by the number of GFP+ Hepa1–6 cells
(Supplementary Fig. 4B). For a cell apoptosis control, Hepa1–6
cells were treated for 24 h with 100 nM sorafenib. At 24 and
72 h, apoptotic Hepa1–6 cells were detected by Annexin V and
7-AAD staining. No increase in the proportion of apoptotic
Hepa1–6 cells was observed compared to GFP-transfected
controls (Fig. 2C), suggesting at least in this setting MET does
not cause oncogene-induced apoptosis.
CD8+ T cells regulate early growth of MET+CAT oncogene-induced
liver cancer
For these studies we used a lower dose of oncogenes (10 lg) to
allow more time for nuanced immune reactions to occur and to
increase sensitivity for GLuc tracking. Cytotoxic CD8+ T cells that
recognize tumor antigen can cause tumor cell apoptosis. How-
ever, chronic exposure to excessive antigen can lead to CD8+ T
cell exhaustion [23], characterized in part by the upregulation
of inhibitory receptors such as PD-1 [24,25]. We hypothesized
that early CD8-mediated immune responses against MET occurvol. 63 j 1181–1189
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JOURNAL OF HEPATOLOGYand result in apoptosis of transformed hepatocytes that was
detected by the early decrease in luciferase following delivery
of MET+CAT oncogenes to the liver. If this theory is correct, we
reasoned that as CD8+ T cells become exhausted, the remaining
transformed GLuc+ hepatocytes would begin to proliferate result-
ing in rising serum luciferase levels, in association with acceler-
ated tumor growth and eventual mortality. To test thisJournal of Hepatology 2015hypothesis, tumor inﬁltrating CD8+ T cells from mice injected
with MET+CAT or AKT+CAT oncogenes were analyzed by ﬂow
cytometry for the expression of PD-1 antigen as a marker of
antigen-experienced exhausted T cells (Fig. 3A). At day 14, PD-1
expression was induced on 33% of the liver CD8+ T cells from
mice where tumors were initiated with the MET+CAT oncogenes.
In contrast, no PD-1 was detected on liver CD8+ T cells from micevol. 63 j 1181–1189 1185
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where tumors were initiated by the AKT+CAT oncogene combina-
tion, or in non-tumor-bearing mice injected with control PT3
vector. These data suggest that CD8+ T cells mediate immune
responses against hepatocytes expressing MET+CAT, but not
AKT+CAT oncogenes.
To determine whether the early differences in serum levels
of luciferase were reﬂecting tumor control by a CD8-mediated
response, luciferase levels after injection of MET+CAT oncoge-
nes were compared in CD8-deﬁcient and WT mice. CD8 deﬁ-
ciency did not affect the ability of hepatocytes to take up
and express SBT vectors. When CD8/ and WT mice were
hydrodynamically transfected with GLuc+HSB2 and MET+CAT,
serum luciferase levels at day 10 were indistinguishable but
by days 15 and 22 they increased in CD8/ mice but not in
WT mice (Fig. 3B), conﬁrming that serum luciferase levels
accurately captured the early CD8-mediated immune response
against MET+CAT transformed hepatocytes. Since the data pre-
sented above conﬁrms that MET+CAT transduced hepatocytes
are immunogenic, we next wanted to determine whether the
transient CD8-mediated response confers a survival advantage.
When CD8/ and WT mice were hydrodynamically transfected
with MET+CAT oncogenes CD8/ mice had a signiﬁcantly
shorter survival time than WT mice (Fig. 3C). The shorter sur-
vival from MET+CAT-induced liver tumors in CD8/ mice sig-
niﬁed that tumor load developed more quickly in these mice.
However, gross morphology at time of morbidity did not reveal
if the shortened survival time was due to quicker tumor devel-
opment and growth or if more tumor nodules were formed. To
determine if CD8+ T cells regulated tumor size (growth) and/or
the number of tumor nodules that develop, we analyzed mice
with MET+CAT-initiated livers at day 42, before frank tumor
is observed, by staining for the surrogate oncogene b-catenin
(CAT) (Fig. 3D). Tumor nodules were quantitated for percent
ﬁeld (100 magniﬁcation), mean tumor nodule size in microns
and the number of tumor nodules. CD8/ mice exhibited
signiﬁcantly more tumor area and mean tumor nodule size
compared to WT mice (Fig. 3E). However, no difference was
observed in the number of tumor nodules between the two
strains of mice (Fig. 3E), suggesting CD8+ T cells regulate tumor
growth rather than the number of malignant foci.
MET+CAT oncogene-induced liver tumor response to IL-18+IL-12
therapies can be accurately tracked by luciferase expression
MET is a broadly expressed oncogene in patients with numer-
ous malignancies [26] and is recognized by cytotoxic T cells
[27]. We reported previously that IL-18+IL-12 therapy was
effective against transplantable tumors seeded in the liver
[28]. Since MET+CAT induced a CD8+ T cell immune response
we hypothesized that IL-18+IL-12 therapy would augment nat-
urally occurring responses against MET+CAT-induced tumors.
Furthermore, we postulate that serum luciferase could be used
to track in real-time the effectiveness of IL-18+IL-12 therapy
against MET+CAT-induced liver tumors originated from GLuc+
hepatocytes. Mice were hydrodynamically transfected with
MET+CAT, HSB2 and GLuc initiating de novo liver tumor forma-
tion in GLuc+ hepatocytes. Liver tumors were allowed to form
and on days 20–24 and 28–31 mice were treated with VC or
with IL-18+IL-12. Serum luciferase levels were not signiﬁcantly
different between the two groups of mice for the ﬁrst 19 days
(Fig. 4A). However, during days 31–61 post-therapy, serum1186 Journal of Hepatology 2015luciferase levels for the VC-treated group increased while the
IL-18+IL-12 treatment group signiﬁcantly decreased to near
undetectable levels (p <0.0001). This result suggests that ther-
apy induced a loss of MET+CAT transformed GLuc+ hepatocytes.
To conﬁrm whether the decreased serum luciferase levels fol-
lowing IL-18+IL-12 therapy were due to reduced MET+CAT
tumor burden, mice were euthanized at day 61. Liver weights,
as well as genomic copy number of MET and CAT oncogenes
measured by qPCR, were quantitated as parameters of tumor
size (Fig. 4B, C). VC-treated mice showed a signiﬁcantly higher
liver weight and MET and CAT copy number than
IL-18+IL-12-treated mice. (Fig. 4B, C). Gross morphological
examination of livers reveals a broad spectrum of tumor bur-
den from nothing observable to substantial burden in the VC
group. On the other hand, no visible tumor nodules were
observed on the livers from mice treated with IL-18+IL-12
(Fig. 5A). Histological analysis reveals livers with frank tumor
in the VC group, which had extensive regions that stained pos-
itively for CAT, while none of the livers in IL-18+IL-12 group
stained positive for CAT (Fig. 5B). H&E analysis of the
IL-18+IL-12 group shows a normal liver structure (Fig. 5C).
H&E analysis of the VC group shows disrupted liver structure
with a thick trabecular pattern containing large eosin+ tumor
cells displaying prominent nucleoli. Serum luciferase levels
were signiﬁcantly higher in mice with morphologically-distin
guishable gross tumors (5 out 8 mice in VC group), which
reﬂected liver weight (Fig. 5D). Serum luciferase levels in
IL-18+IL-12-treated mice were at background levels and liver
weights were normal (1 g or less). Linear regression analysis
comparing serum luciferase levels and liver weights for all
mice were highly signiﬁcant (Fig. 5E). Collectively we demon-
strate for the ﬁrst time that SBT-delivered oncogene-induced
liver tumors are amenable for studying the efﬁcacy of
immunotherapeutic approaches and that GLuc vector can be
used to assess the effectiveness of these therapies.vol. 63 j 1181–1189
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Hydrodynamic transfection of SBT vectors provides an efﬁcient
and rapid system to functionally evaluate oncogenic collabora-
tion in the formation of de novo liver tumors. Furthermore, this
technique permits the assessment of inﬂammation-inﬂuenced
somatic mutations, delineating cancer ‘‘drivers’’ from ‘‘passengers’’
[7,29]. SBT delivery of oncogenes initiates tumor development
and subsequent progression, which permits the study of inﬂam-
matory events driving liver tumor formation, progression and
immune escape. However, the time to morbidity for tumors initi-
ated by the SBT system can vary signiﬁcantly. Thus, a tracking
approach that quantiﬁes tumor growth patterns and therapeutic
interventions in living mice, without the need for costly and
time-consuming imaging, or euthanasia and analysis of cohorts,
would allow for efﬁcient delineation of molecular and immune
regulatory events that regulate tumor initiation and growth.
We found co-delivery of a GLuc expression vector in combination
with oncogenes accurately tracked liver tumor growth initiated
using the SBT system. Decreasing the amount of GLuc decreases
the background serum luciferase levels. Reducing the ratio of
oncogene to GLuc allows a higher frequency of hepatocytes to
take up both oncogenes and GLuc allowing for a higher frequency
of luciferase expressing transformed hepatocytes and increased
sensitivity for tracking tumor growth with GLuc.
Solid tumors often grow in a complex nonlinear fashion
[20,21]. Tumor proliferation and apoptosis can be inﬂuenced in
various ways by different factors, such as immune recognition
[30,31] and the presence of angiogenic factors needed to form
tumor vasculature [32]. Determining these tumor growthJournal of Hepatology 2015inﬂection points could offer valuable biological insights into
tumor growth as well as informing the timing and outcome of
possible therapeutic interventions. We determined that serum
luciferase levels closely tracked tumor-induced changes in liver
size as detected and quantitated by MRI analysis. Thus, we show
here for the ﬁrst time that the nonlinear growth patterns of
oncogene-induced liver tumors can be tracked in real-time by
serum luciferase levels from hepatocytes using an integrated
GLuc expression vector. In addition to tracking SBT-induced
tumor growth, the stable expression of integrated GLuc should
also be useful in tracking tumors initiated by carcinogens/
mutagen such as DEN. Furthermore, the changes in stable
luciferase expression from GLuc could be useful in monitoring
liver toxicity or studies employing partial hepatectomy.
MET, which is widely expressed in numerous malignancies
[26], was also demonstrated to be a tumor antigen recognized
by cytotoxic T cells (CTLs) [27]. In our model we found human
MET, but not human CAT, induced hepatocyte apoptosis that
was at least partially mediated by CD8+ T cells. This result sug-
gested human MET in a mouse model may also induce cytotoxic
T cells. Some MET-induced TUNEL staining was still present in
CD8/ mice suggesting that MET may also induce some
oncogene-driven apoptosis. Interestingly delivering MET to B
cell/ mice or depleting macrophages with clodronate increased
the number of TUNEL+ hepatocytes suggesting these cells offer
partial protection from MET-induced apoptosis. Examination of
differences in early growth patterns revealed that CD8+ T cells
regulated the persistence of MET+CAT transduced hepatocytes
during the time span shortly after transformation. Furthermore,
CD8-deﬁcient mice succumbed to MET+CAT-induced liver tumorsvol. 63 j 1181–1189 1187
Th
vie
Research Article
more rapidly than did their WT counterpart. Histological exami-
nation of MET+CAT-initiated tumors shows CD8/ mice had lar-
ger tumor nodules, as well as a similar number of tumor nodules.
Taken together, this suggests CD8 T cells regulate the growth of
MET+CAT-induced liver tumors. However, the larger tumor
nodules could also be masking the total number of nodules in
CD8 deﬁcient mice as they may be coalescing in some cases.
To our knowledge this is the ﬁrst report to use immunother-
apy to treat SBT-induced liver tumors. We previously reported
that IL-18+IL-12 was a potent immunotherapeutic regimen
against implanted tumors [28]. Because human CTLs have been
shown to respond to MET [27] and we found mouse CD8+ T cells
responded to human MET, we examined the immunotherapeutic
potential of treating mice bearing MET+CAT tumors with
IL-18+IL-12. We found treating mice with IL-18+IL-12 ablated
MET+CAT-initiated liver tumors and restored liver morphology
that was accurately tracked by serum luciferase quantitation,
suggesting that this technology can be used to monitor preclini-
cal immunotherapeutic approaches against liver cancer.
Immunohistochemical analysis of CAT staining demonstrated
that IL-18+IL-12 also cleared all detectable microscopic tumors,
in addition to the absence of grossly detectable visible tumors
as described above. This data suggests IL-18+IL-12 therapy may
elicit an anti-tumor response in humans mediated by MET
responding CTLs.
In summary, we have shown that hydrodynamic delivery of
GLuc vector can be used as a simple cost-effective, blood-based
approach for tracking the progression of pathologically distinct
liver tumors, evaluation of immunologic responses and efﬁcacy
of therapeutic interventions in individual mice. This approach
can be used to track nonlinear tumor progression in real-time
and identify potentially important biological regulatory points
at which therapeutic intervention may hold greater potential
for controlling liver tumor burden. Furthermore, IL-18+IL-12 is
an effective therapy against antigenic MET-induced liver tumors.Financial support
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